Clinical Trials Logo

Filter by:
NCT ID: NCT00413660 Completed - Clinical trials for Arthritis, Rheumatoid

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

Start date: January 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.

NCT ID: NCT00413283 Completed - Cancer Clinical Trials

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.

NCT ID: NCT00413218 Completed - Mycoses Clinical Trials

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Start date: March 8, 2007
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.

NCT ID: NCT00413205 Completed - Emphysema Clinical Trials

TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)

Start date: January 2007
Phase: Phase 2
Study type: Interventional

This 2 arm study will investigate the efficacy, safety and tolerability of RAR Gamma versus placebo in ex-smokers with moderate or severe emphysema treated with optimal COPD therapy. Following optimization of COPD therapy (up to 6 weeks) patients will be randomized to receive either RAR Gamma (5mg) or placebo once daily using a 2:1 ratio (active:placebo), in addition to their standard therapy. Following the double-blind treatment period, patients will enter a 4-week follow-up period. The anticipated time on study period is 1-2 years, and the target sample size is 100-500 individuals.

NCT ID: NCT00413010 Completed - Clinical trials for Generalized Anxiety Disorder

Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).

Start date: December 2006
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of pregabalin as compared to placebo in the treatment of patients with general anxiety disorder (GAD). Efficacy will be measured by the improvement in the total Hamilton Anxiety Rating Scale (HAM-A) scores from baseline observed following 8 weeks of double-blind treatment or at earlier termination during the double-blind treatment phase and analyzed using a mixed linear model for repeated measures.

NCT ID: NCT00412984 Completed - Atrial Fibrillation Clinical Trials

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

ARISTOTLE
Start date: December 31, 2006
Phase: Phase 3
Study type: Interventional

The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.

NCT ID: NCT00412893 Completed - Aspergillosis Clinical Trials

Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis

Start date: March 7, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.

NCT ID: NCT00412737 Completed - Influenza Clinical Trials

A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.

Start date: n/a
Phase: Phase 4
Study type: Interventional

This 2 arm study will evaluate the efficacy and safety of Tamiflu in the seasonal prophylaxis of influenza in immunocompromised patients (as represented by transplant recipients). Transplant recipients enrolled when influenza is circulating in the community will be randomized to receive Tamiflu syrup or capsules 30mg-75mg daily (depending on body weight) or placebo for 12 weeks. Influenza symptoms and safety data will be recorded throughout the study. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals.

NCT ID: NCT00411541 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia

Start date: April 1995
Phase: Phase 4
Study type: Interventional

Studies in the 1970s and 1980s suggested that the outcome of childhood acute lymphoblastic leukemia could be improved by intensification of conventional continuation chemotherapy with pulses of vincristine sulfate and steroids. We aimed to investigate the efficacy and toxic effects of vincristine-dexamethasone pulses as an addition to the continuation-therapy phase in a large cohort of children with intermediate-risk disease who were treated with the BFM treatment strategy

NCT ID: NCT00411424 Completed - Clinical trials for Rheumatoid Arthritis

Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis

Start date: September 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety and tolerability of the new medication ASK8007, and to study whether it has a beneficial effect on joint inflammation in patients with rheumatoid arthritis.